41![103949s5171 Peginterferon (Rebetol) Clinical PREA 103949s5171 Peginterferon (Rebetol) Clinical PREA](https://www.pdfsearch.io/img/282f52043bc52739729399657e68c464.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
42![PegIntron: Memo, Alpha interferons and liver transplant rejection PegIntron: Memo, Alpha interferons and liver transplant rejection](https://www.pdfsearch.io/img/ff104729cb5a1aaa843ea7aeb9c4587b.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
43![NEW EXCEPTION DRUG STATUS LISTINGS: NEW EXCEPTION DRUG STATUS LISTINGS:](https://www.pdfsearch.io/img/beb01c3570a9d8689a6b0c3258cb1a59.jpg) | Add to Reading ListSource URL: formulary.drugplan.health.gov.sk.caLanguage: English - Date: 2014-06-26 15:57:56
|
---|
44![Pediatric Focused Safety Review: Peginterferon alfa-2b (PegIntron) Pediatric Focused Safety Review: Peginterferon alfa-2b (PegIntron)](https://www.pdfsearch.io/img/7ce22b8dd7cdbc7b993795762a8d1ed3.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
45![of Health and Human Services Department Public Health Service of Health and Human Services Department Public Health Service](https://www.pdfsearch.io/img/0ee1da088770d04d53baba5786e3bade.jpg) | Add to Reading ListSource URL: www.fda.govLanguage: English |
---|
46![DESIGNATED HIGH COST DRUGS To reduce the potential for wastage, claims for designated high cost drugs that require special authorization (SA) are subject to a maximum days supply (e.g. 30 days) when administered at stand DESIGNATED HIGH COST DRUGS To reduce the potential for wastage, claims for designated high cost drugs that require special authorization (SA) are subject to a maximum days supply (e.g. 30 days) when administered at stand](https://www.pdfsearch.io/img/82b1832635c2316416caafa8e73ddf64.jpg) | Add to Reading ListSource URL: www.gnb.caLanguage: English - Date: 2014-08-20 14:17:10
|
---|
47![The role of EMA and drug approvals for chronic HBV/HCV Summit Conference Hepatitis B and C Brussels, 14-15 October[removed]Marco Cavaleri The role of EMA and drug approvals for chronic HBV/HCV Summit Conference Hepatitis B and C Brussels, 14-15 October[removed]Marco Cavaleri](https://www.pdfsearch.io/img/1131344651a69d7bce6b3bec110ca089.jpg) | Add to Reading ListSource URL: www.hepbcppa.orgLanguage: English - Date: 2014-04-30 06:48:45
|
---|
48![HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYLATRON safely and effectively. See full prescribing information for SYLATRON. SYLATRON™ (peginterferon alfa-2b) HIGHLIGHTS OF PRESCRIBING INFORMATION These highlights do not include all the information needed to use SYLATRON safely and effectively. See full prescribing information for SYLATRON. SYLATRON™ (peginterferon alfa-2b)](https://www.pdfsearch.io/img/0a42b6db106f08a7c92c45ff2458ef84.jpg) | Add to Reading ListSource URL: www.merck.comLanguage: English - Date: 2014-08-21 16:32:47
|
---|
49![MEDICATION GUIDE SYLATRON™ (SY-LA-TRON) (Peginterferon alfa-2b) Read this Medication Guide before you start taking SYLATRON, and each time you get a refill. There may be new information. This Medication Guide does not MEDICATION GUIDE SYLATRON™ (SY-LA-TRON) (Peginterferon alfa-2b) Read this Medication Guide before you start taking SYLATRON, and each time you get a refill. There may be new information. This Medication Guide does not](https://www.pdfsearch.io/img/f6187ad9ce51d342491ff3fb3087ab45.jpg) | Add to Reading ListSource URL: www.merck.comLanguage: English - Date: 2014-08-21 16:32:46
|
---|
50![SYLATRON™ (peginterferon alfa-2b) for injection, for subcutaneous use SYLATRON™ (peginterferon alfa-2b) for injection, for subcutaneous use](https://www.pdfsearch.io/img/18d07197b189232ef3300f694c814009.jpg) | Add to Reading ListSource URL: www.accessdata.fda.govLanguage: English - Date: 2012-12-28 10:56:59
|
---|